Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 The number of patients demonstrating a metabolic response following 14 and 28 days of treatment

From: Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma

  After 14 days After 28 days
  Metabolic response Metabolic progress Metabolic response Metabolic progress
SULpeaka 9/28 8/28 11/28 4/28
SUVmax 8/32 5/32 12/30 6/30
TLG2.5 14/32 6/32 14/30 6/30
TLG50 15/32 3/32 12/30 5/30
HottestSULpeaka 9/28 7/28 10/28 5/28
HottestSUVmax 8/32 4/32 8/30 4/30
HottestTLG2.5 14/32 6/32 14/30 6/30
HottestTLG50 17/32 5/32 15/30 6/30
  1. aAssessed according to PERCIST1.0. Only 28 patients had a lesion that fulfilled the PERCIST criteria.